A 6-month-old infant boy is brought to the clinic for a check-up by a couple who recently adopted him from foster care. The biological mother was from a rehabilitation facility and was found incompetent to care for the child, hence he was handed over to foster care. No other information is available regarding his prenatal or birth history. On examination, his weight is found to be below the 3rd percentile. Physical appearance is remarkable for midfacial hypoplasia with a flattened nasal bridge, smooth philtrum, and thin lips. Auscultation reveals a grade 3/6 holosystolic murmur at the left lower sternal border. Developmental delay is noted as well. Which of the following teratogens is most likely to be associated with the infant's presentation?
Q182
A 42-year-old man comes to the emergency department because of tingling in his hands and legs and palpitations for 1 week. He has also had severe cramping in his hands, feet, and abdomen during this period. Three months ago, he was hospitalized for acute pancreatitis. He discharged himself against medical advice at that time. There is no family history of illness. He does not smoke. He drinks 2–3 beers and a pint of vodka daily. He has a history of using intravenous heroin. He has not had a stable job for a year. He is only oriented to place and person. His temperature is 37.1°C (98.8°F), pulse is 90/min, and blood pressure is 110/96 mm Hg. There is a carpopedal spasm while measuring his blood pressure. Cardiopulmonary examination shows no abnormalities. Deep tendon reflexes are 4+ bilaterally. Neurologic examination shows no focal findings. Which of the following is the most appropriate pharmacotherapy?
Q183
A 30-year-old female with a history of epilepsy becomes pregnant. Her epilepsy has been well controlled by taking a medication that inhibits GABA transaminase and blocks voltage-gated sodium and calcium channels. Her obstetrician informs her that her epilepsy medication has been shown to have teratogenic effects. Of the following, which teratogenic effect is this woman's medication most likely to cause?
Q184
A 62-year-old man with a history of coronary artery disease comes to the emergency department with substernal chest pain for several hours. An ECG shows no abnormalities. Troponin T test results are negative. The patient is admitted to the hospital and treated with intravenous nitroglycerin, with an initial resolution of his symptoms. After 6 hours of continuous infusion of nitroglycerin, he reports increasing chest pain. The underlying cause of this patient's recurrent symptoms is most likely to also occur in treatment with which of the following drugs?
Q185
A 60-year-old woman is brought to the emergency department by paramedics after being found unresponsive. It is not possible to obtain a history. Her blood pressure is 75/30 mmHg and pulse is 108/min. Her extremities are cool and mottled. She is admitted to the intensive care unit (ICU) for further supportive care, where she is started on a norepinephrine intravenous drip. After several hours on this infusion, which of the following changes in vitals would be expected?
Q186
A 56-year-old man with type 2 diabetes mellitus comes to the physician for a follow-up examination. He reports that he has been compliant with his current antidiabetic medication regimen. His hemoglobin A1c concentration is 8.5%. The physician prescribes a drug that reversibly inhibits a membrane-bound enzyme that hydrolyzes carbohydrate bonds. Which of the following drugs was most likely added to this patient's medication regimen?
Q187
A 72-year-old man with type 2 diabetes mellitus, hypertension, and systolic heart failure comes to the physician because of a 5-day history of progressively worsening shortness of breath at rest. Physical examination shows jugular venous distention, diffuse crackles over the lower lung fields, and bilateral lower extremity edema. As a part of treatment, he is given a derivative of a hormone that acts by altering guanylate cyclase activity. This drug has been found to reduce pulmonary capillary wedge pressure and causes systemic hypotension as an adverse effect. The drug is most likely a derivative of which of the following hormones?
Q188
A 49-year-old man being treated for Helicobacter pylori infection presents to his primary care physician complaining of lower back pain. His physician determines that a non-steroidal anti-inflammatory drug (NSAID) would be the most appropriate initial treatment. Which of the following is the most appropriate NSAID for this patient?
Q189
A 37-year-old man is brought to the emergency department following a motor vehicle collision. His temperature is 38.1°C (100.6°F), pulse is 39/min, respirations are 29/min, and blood pressure is 58/42 mm Hg. There is no improvement in his blood pressure despite adequate fluid resuscitation. A drug is administered that causes increased IP3 concentrations in arteriolar smooth muscle cells and increased cAMP concentrations in cardiac myocytes. This drug only has a negligible effect on cAMP concentration in bronchial smooth muscle cells. Which of the following sets of cardiovascular changes is most likely following administration of this drug?
Q190
A 64-year-old man presents to the emergency department with sudden onset of pleuritic chest pain and dyspnea on exertion. He has a history of lung cancer and is currently being treated with outpatient chemotherapy. His temperature is 98.9°F (37.2°C), blood pressure is 111/64 mmHg, pulse is 130/min, respirations are 25/min, and oxygen saturation is 90% on room air. Initial laboratory values in the emergency department are seen below.
Hemoglobin: 8.2 g/dL
Hematocrit: 26%
Leukocyte count: 7,700/mm^3 with normal differential
Platelet count: 157,000/mm^3
A CT angiogram demonstrates a blood clot in the pulmonary vasculature. The patient is started on heparin and he is admitted to the ICU. Laboratory values 6 days later are shown below.
Hemoglobin: 8.0 g/dL
Hematocrit: 25%
Leukocyte count: 7,500/mm^3 with normal differential
Platelet count: 22,000/mm^3
Which of the following is the most appropriate next step in management?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 181: A 6-month-old infant boy is brought to the clinic for a check-up by a couple who recently adopted him from foster care. The biological mother was from a rehabilitation facility and was found incompetent to care for the child, hence he was handed over to foster care. No other information is available regarding his prenatal or birth history. On examination, his weight is found to be below the 3rd percentile. Physical appearance is remarkable for midfacial hypoplasia with a flattened nasal bridge, smooth philtrum, and thin lips. Auscultation reveals a grade 3/6 holosystolic murmur at the left lower sternal border. Developmental delay is noted as well. Which of the following teratogens is most likely to be associated with the infant's presentation?
A. Lithium
B. Tobacco
C. Phenytoin
D. Alcohol (Correct Answer)
E. Cocaine
Explanation: ***Alcohol***
- The combination of **facial dysmorphology** (midfacial hypoplasia, flattened nasal bridge, smooth philtrum, thin lips), **growth restriction** (weight below 3rd percentile), **cardiac defect** (holosystolic murmur), and **developmental delay** is highly characteristic of **Fetal Alcohol Syndrome (FAS)**.
- The biological mother's history of being in a **rehabilitation facility** suggests a potential history of substance abuse, making maternal alcohol consumption during pregnancy a strong possibility.
*Lithium*
- Maternal lithium use is associated with **Ebstein's anomaly**, a specific congenital heart defect, but typically does not cause the widespread facial dysmorphism and growth restriction seen in this infant.
- While it can cause cardiac defects, the overall constellation of findings points away from lithium as the primary teratogen.
*Tobacco*
- Maternal tobacco use is primarily associated with **low birth weight**, premature birth, and an increased risk of specific birth defects like **cleft lip and palate**.
- It does not typically cause the characteristic facial features, significant cardiac anomalies, or widespread developmental delay observed in this case.
*Phenytoin*
- Phenytoin, an anticonvulsant, can cause **fetal hydantoin syndrome**, characterized by specific facial features (e.g., hypertelorism, short nose, cleft lip/palate), **digital hypoplasia**, and intellectual disability.
- While it can cause some overlapping features like growth deficiency and developmental delay, the specific craniofacial features described for this infant are more typical of FAS.
*Cocaine*
- Cocaine exposure during pregnancy is associated with a range of problems including **preterm birth**, **placental abruption**, and **genitourinary defects**.
- Its teratogenic effects often involve vascular disruption leading to limb defects or cerebral infarctions, rather than the characteristic facial dysmorphology and cardiac defects described in this infant.
Question 182: A 42-year-old man comes to the emergency department because of tingling in his hands and legs and palpitations for 1 week. He has also had severe cramping in his hands, feet, and abdomen during this period. Three months ago, he was hospitalized for acute pancreatitis. He discharged himself against medical advice at that time. There is no family history of illness. He does not smoke. He drinks 2–3 beers and a pint of vodka daily. He has a history of using intravenous heroin. He has not had a stable job for a year. He is only oriented to place and person. His temperature is 37.1°C (98.8°F), pulse is 90/min, and blood pressure is 110/96 mm Hg. There is a carpopedal spasm while measuring his blood pressure. Cardiopulmonary examination shows no abnormalities. Deep tendon reflexes are 4+ bilaterally. Neurologic examination shows no focal findings. Which of the following is the most appropriate pharmacotherapy?
A. Magnesium sulfate (Correct Answer)
B. Lorazepam
C. Sodium bicarbonate
D. Fomepizole
E. Vitamin B1 (thiamine)
Explanation: ***Magnesium sulfate***
- The patient exhibits symptoms like **tingling**, **palpitations**, **severe cramping** (hands, feet, abdomen), **carpopedal spasm** (Trousseau's sign), and **hyperreflexia (4+)**, which are classic signs of **hypocalcemia** or **hypomagnesemia**.
- Given his history of **alcohol abuse**, **intravenous drug use**, and recent **pancreatitis**, **hypomagnesemia** is a likely diagnosis, often leading to secondary hypocalcemia. **Magnesium sulfate** is the appropriate treatment.
*Lorazepam*
- Lorazepam is a **benzodiazepine** used to treat seizures, anxiety, and alcohol withdrawal.
- While the patient has a history of alcohol use, his current symptoms are more indicative of electrolyte imbalance (hypomagnesemia/hypocalcemia) rather than acute alcohol withdrawal or seizures.
*Sodium bicarbonate*
- **Sodium bicarbonate** is used to treat metabolic acidosis or certain poisonings.
- There is no indication of acidosis in the given clinical presentation; the symptoms are primarily related to neuromuscular irritability.
*Fomepizole*
- **Fomepizole** is an antidote used in cases of **methanol** or **ethylene glycol poisoning**.
- The patient's presentation does not suggest ingestion of these toxic alcohols.
*Vitamin B1 (thiamine)*
- **Thiamine** is crucial for preventing and treating **Wernicke-Korsakoff syndrome** in patients with chronic alcohol abuse.
- While appropriate for patients with alcohol abuse, it does not directly address the acute neuromuscular irritability and tetany symptoms (tingling, carpopedal spasm, hyperreflexia) observed in this patient.
Question 183: A 30-year-old female with a history of epilepsy becomes pregnant. Her epilepsy has been well controlled by taking a medication that inhibits GABA transaminase and blocks voltage-gated sodium and calcium channels. Her obstetrician informs her that her epilepsy medication has been shown to have teratogenic effects. Of the following, which teratogenic effect is this woman's medication most likely to cause?
A. Limb defects
B. Neural tube defect (Correct Answer)
C. Renal damage
D. Ebstein's anomaly
E. Discolored teeth
Explanation: ***Neural tube defect***
- The medication described, which **inhibits GABA transaminase** and has multiple mechanisms including effects on voltage-gated channels, is **valproic acid** (valproate).
- **Valproic acid** is the antiepileptic drug with the **highest risk of neural tube defects** (e.g., spina bifida), with an incidence of approximately 1-2% when taken during pregnancy.
- This teratogenic effect occurs primarily during the first trimester and is believed to be due to interference with **folate metabolism** and **histone deacetylase inhibition**, which are crucial for proper neural tube closure.
- Folic acid supplementation is recommended for women of childbearing age taking valproate.
*Limb defects*
- **Limb defects** (e.g., phocomelia, limb reduction defects) are classically associated with **thalidomide** exposure during early pregnancy.
- While **phenytoin** (fetal hydantoin syndrome) can cause limb abnormalities including hypoplastic nails and distal phalanges, this is not the primary teratogenic concern with valproic acid.
*Renal damage*
- **Fetal renal damage** can be caused by medications such as **ACE inhibitors**, **ARBs**, and **NSAIDs** when taken during pregnancy.
- This is not a characteristic teratogenic effect of valproic acid or other antiepileptic medications.
*Ebstein's anomaly*
- **Ebstein's anomaly**, a congenital heart defect characterized by apical displacement of the tricuspid valve, is most notably associated with **lithium exposure** during the first trimester of pregnancy.
- This cardiac anomaly is not typically linked to valproic acid or other anticonvulsant medications.
*Discolored teeth*
- **Discolored teeth** (yellow-brown staining) and enamel hypoplasia are classic adverse effects of **tetracycline antibiotics** when administered during pregnancy (second and third trimesters) or early childhood.
- This effect is not associated with antiepileptic medications.
Question 184: A 62-year-old man with a history of coronary artery disease comes to the emergency department with substernal chest pain for several hours. An ECG shows no abnormalities. Troponin T test results are negative. The patient is admitted to the hospital and treated with intravenous nitroglycerin, with an initial resolution of his symptoms. After 6 hours of continuous infusion of nitroglycerin, he reports increasing chest pain. The underlying cause of this patient's recurrent symptoms is most likely to also occur in treatment with which of the following drugs?
A. Alprazolam
B. Methicillin
C. Phenylephrine (Correct Answer)
D. Hydrocodone
E. Levodopa
Explanation: ***Phenylephrine***
- The patient is experiencing **tachyphylaxis** to nitroglycerin, defined as rapidly decreasing response to a drug with continuous exposure (within hours).
- **Phenylephrine** (alpha-1 adrenergic agonist) is well-known to cause **rapid tachyphylaxis** with continuous or repeated administration, particularly with IV infusions.
- Both nitroglycerin and phenylephrine cause tachyphylaxis through **receptor desensitization and downregulation** with sustained exposure.
- This is a classic pharmacology teaching point: **nitrates and direct-acting sympathomimetics** (like phenylephrine) share this mechanism of rapid tolerance.
*Hydrocodone*
- Hydrocodone is an **opioid analgesic** that can develop **tolerance** with chronic use.
- However, opioid tolerance develops gradually over days to weeks, not the acute tachyphylaxis (hours) seen with nitroglycerin.
- The mechanism and time course are distinct from the rapid receptor desensitization seen with nitrates.
*Alprazolam*
- Alprazolam is a **benzodiazepine** used for anxiety and can develop tolerance with long-term use.
- This tolerance is a gradual process occurring over weeks to months, not the rapid tachyphylaxis seen here.
- The mechanism involves changes in GABA receptor function, distinct from the acute desensitization with nitrates.
*Methicillin*
- Methicillin is a **beta-lactam antibiotic** that does not cause pharmacodynamic tachyphylaxis.
- Bacterial resistance can develop through mutations and selection, which is an entirely different phenomenon from drug tachyphylaxis.
*Levodopa*
- Levodopa is used for **Parkinson's disease** and can lead to "wearing off" effects and motor fluctuations.
- These phenomena are primarily due to disease progression and changes in striatal dopamine storage capacity, not acute tachyphylaxis.
- The time course is over months to years, not hours like nitroglycerin tachyphylaxis.
Question 185: A 60-year-old woman is brought to the emergency department by paramedics after being found unresponsive. It is not possible to obtain a history. Her blood pressure is 75/30 mmHg and pulse is 108/min. Her extremities are cool and mottled. She is admitted to the intensive care unit (ICU) for further supportive care, where she is started on a norepinephrine intravenous drip. After several hours on this infusion, which of the following changes in vitals would be expected?
A. Blood pressure decreases; pulse decreases
B. Blood pressure increases; pulse increases
C. Blood pressure decreases; pulse increases
D. Blood pressure increases; pulse remains unchanged
E. Blood pressure increases; pulse decreases (Correct Answer)
Explanation: ***Blood pressure increases; pulse decreases***
- **Norepinephrine** is a potent **vasoconstrictor** that increases systemic vascular resistance, leading to an **increase in blood pressure**.
- The increased blood pressure activates **baroreceptors**, triggering a **reflex bradycardia** (decreased heart rate or pulse) to maintain cardiovascular homeostasis.
*Blood pressure decreases; pulse decreases*
- **Norepinephrine** is expected to *increase* blood pressure, not decrease it.
- A decrease in both blood pressure and pulse in this context would suggest worsening shock or an adverse reaction, not a therapeutic effect.
*Blood pressure increases; pulse increases*
- While norepinephrine increases blood pressure, the direct stimulation of beta-1 receptors on the heart causing an increased heart rate is often *overridden* by the **baroreceptor reflex** that reduces heart rate due to the sharp rise in blood pressure.
- An increase in both parameters is less typical with norepinephrine as the predominant effect on heart rate is usually reflex bradycardia.
*Blood pressure decreases; pulse increases*
- **Norepinephrine** is a powerful pressor agent and would not cause a *decrease* in blood pressure, especially in a hypotensive patient.
- This combination of vital signs would indicate worsening **hypotension** and **tachycardia**, often seen in uncontrolled shock.
*Blood pressure increases; pulse remains unchanged*
- While **blood pressure increases** as expected with norepinephrine, it is very unlikely for the **pulse to remain unchanged** due to the robust **baroreceptor reflex** responding to the significant rise in blood pressure.
- The reflex arc aims to normalize blood pressure by modulating heart rate, typically causing a decrease.
Question 186: A 56-year-old man with type 2 diabetes mellitus comes to the physician for a follow-up examination. He reports that he has been compliant with his current antidiabetic medication regimen. His hemoglobin A1c concentration is 8.5%. The physician prescribes a drug that reversibly inhibits a membrane-bound enzyme that hydrolyzes carbohydrate bonds. Which of the following drugs was most likely added to this patient's medication regimen?
A. Canagliflozin
B. Miglitol (Correct Answer)
C. Linagliptin
D. Pramlintide
E. Rosiglitazone
Explanation: ***Miglitol***
- Miglitol is an **alpha-glucosidase inhibitor** that reversibly inhibits enzymes like sucrase and maltase in the brush border of the small intestine.
- This action **delays carbohydrate digestion and absorption**, reducing postprandial glucose excursions, which fits the description of inhibiting a "membrane-bound enzyme that hydrolyzes carbohydrate bonds."
*Canagliflozin*
- Canagliflozin is a **sodium-glucose co-transporter 2 (SGLT2) inhibitor** that acts in the kidney to reduce glucose reabsorption, leading to increased glucose excretion in the urine.
- It does not inhibit carbohydrate-hydrolyzing enzymes in the gastrointestinal tract.
*Linagliptin*
- Linagliptin is a **dipeptidyl peptidase-4 (DPP-4) inhibitor** that increases the levels of incretin hormones (GLP-1 and GIP), thereby enhancing glucose-dependent insulin secretion and suppressing glucagon secretion.
- This mechanism is distinct from inhibiting carbohydrate hydrolysis.
*Pramlintide*
- Pramlintide is an **amylin analog** that slows gastric emptying, suppresses postprandial glucagon secretion, and promotes satiety.
- It works by mimicking the action of amylin, not by inhibiting enzymes that break down carbohydrates.
*Rosiglitazone*
- Rosiglitazone is a **thiazolidinedione (TZD)** that acts as an agonist for peroxisome proliferator-activated receptor-gamma (PPAR-γ) to improve insulin sensitivity in peripheral tissues.
- Its mechanism of action is related to gene transcription and insulin sensitization rather than direct inhibition of carbohydrate-hydrolyzing enzymes.
Question 187: A 72-year-old man with type 2 diabetes mellitus, hypertension, and systolic heart failure comes to the physician because of a 5-day history of progressively worsening shortness of breath at rest. Physical examination shows jugular venous distention, diffuse crackles over the lower lung fields, and bilateral lower extremity edema. As a part of treatment, he is given a derivative of a hormone that acts by altering guanylate cyclase activity. This drug has been found to reduce pulmonary capillary wedge pressure and causes systemic hypotension as an adverse effect. The drug is most likely a derivative of which of the following hormones?
A. Prostacyclin
B. Aldosterone
C. Somatostatin
D. Brain natriuretic peptide (Correct Answer)
E. Angiotensin II
Explanation: ***Brain natriuretic peptide***
- **Brain natriuretic peptide (BNP)** derivatives, like nesiritide, activate **guanylate cyclase**, leading to increased cGMP, vasodilation, and reduced preload/afterload, alleviating heart failure symptoms.
- The patient's symptoms (shortness of breath, jugular venous distention, crackles, edema) are classic for **acute decompensated heart failure**, making a BNP derivative an appropriate treatment.
*Prostacyclin*
- **Prostacyclin** analogs (e.g., epoprostenol) are primarily used for **pulmonary hypertension** due to their potent vasodilatory effects in the pulmonary circulation.
- They activate **adenylyl cyclase** (increasing cAMP), not guanylate cyclase (which increases cGMP), representing a different mechanism of action.
*Aldosterone*
- **Aldosterone** is a mineralocorticoid that promotes **sodium and water retention** and potassium excretion, exacerbating heart failure symptoms.
- Its antagonists (e.g., spironolactone) are used in chronic heart failure but do not directly act via guanylate cyclase for acute symptom relief.
*Somatostatin*
- **Somatostatin** is a peptide hormone that **inhibits the secretion of various hormones**, including growth hormone, insulin, and glucagon.
- It is used in conditions like acromegaly or variceal bleeding and has no direct role in heart failure management via guanylate cyclase.
*Angiotensin II*
- **Angiotensin II** is a potent vasoconstrictor and a key component of the **renin-angiotensin-aldosterone system (RAAS)**, contributing to hypertension and heart failure progression.
- Drugs targeting angiotensin II (ACE inhibitors, ARBs) reduce its effects but do not act by directly altering guanylate cyclase activity; instead, they block its receptors or synthesis.
Question 188: A 49-year-old man being treated for Helicobacter pylori infection presents to his primary care physician complaining of lower back pain. His physician determines that a non-steroidal anti-inflammatory drug (NSAID) would be the most appropriate initial treatment. Which of the following is the most appropriate NSAID for this patient?
A. Aspirin
B. Ibuprofen
C. Celecoxib (Correct Answer)
D. Naproxen
E. Diclofenac
Explanation: **Celecoxib**
- This patient is being treated for a *Helicobacter pylori* infection, indicating a potential risk for **gastrointestinal complications** like ulcers. **Celecoxib** is a selective **COX-2 inhibitor**, which has a lower risk of causing GI side effects compared to non-selective NSAIDs.
- Its selective inhibition of COX-2 helps reduce pain and inflammation while largely sparing the **COX-1 enzyme**, which is responsible for maintaining the **gastric mucosal lining**.
*Aspirin*
- **Aspirin** is a non-selective NSAID that inhibits both **COX-1** and **COX-2** enzymes.
- Inhibition of COX-1 can lead to a significant increase in the risk of **gastrointestinal bleeding** and **ulcer formation**, which is particularly concerning for a patient with an *H. pylori* infection.
*Ibuprofen*
- **Ibuprofen** is a non-selective NSAID that can cause **gastrointestinal irritation** and damage by inhibiting **COX-1**.
- Its use would increase the risk of worsening the patient's existing **gastrointestinal vulnerability** due to the *H. pylori* infection.
*Naproxen*
- **Naproxen** is another non-selective NSAID with a relatively long half-life, making its **gastrointestinal side effects** potentially more prolonged and severe than some other non-selective NSAIDs.
- It carries a **higher risk for GI bleeding** and ulcers compared to selective COX-2 inhibitors, especially in patients with pre-existing GI issues.
*Diclofenac*
- **Diclofenac** is a non-selective NSAID that carries a risk of **gastrointestinal adverse events**, although some studies suggest it might have a slightly better GI safety profile than other non-selective NSAIDs at lower doses.
- However, in a patient with *H. pylori*, it still poses a significant risk for **ulcers** and bleeding compared to a COX-2 selective inhibitor.
Question 189: A 37-year-old man is brought to the emergency department following a motor vehicle collision. His temperature is 38.1°C (100.6°F), pulse is 39/min, respirations are 29/min, and blood pressure is 58/42 mm Hg. There is no improvement in his blood pressure despite adequate fluid resuscitation. A drug is administered that causes increased IP3 concentrations in arteriolar smooth muscle cells and increased cAMP concentrations in cardiac myocytes. This drug only has a negligible effect on cAMP concentration in bronchial smooth muscle cells. Which of the following sets of cardiovascular changes is most likely following administration of this drug?
E. Heart Rate No change Blood Pressure ↑ Systemic Vascular Resistance ↑
Explanation: ***Heart Rate ↑ Blood Pressure ↑ Systemic Vascular Resistance ↑***
- This drug profile describes **norepinephrine**, which has potent **α1 (increases IP3)** and **β1 (increases cAMP in heart)** agonist activity with minimal β2 effects.
- The increase in **IP3 in arteriolar smooth muscle cells** leads to **vasoconstriction** via increased intracellular calcium, resulting in markedly **increased systemic vascular resistance (SVR)**.
- The increase in **cAMP in cardiac myocytes** provides **positive inotropy (contractility) and chronotropy (heart rate)** through β1 receptor stimulation.
- The combined effects of increased cardiac output and increased SVR result in a **significant increase in blood pressure**, making this the ideal vasopressor for distributive shock.
- Note: While baroreceptor reflexes might blunt the heart rate increase in normal states, in severe shock with autonomic dysfunction, the direct β1 effect predominates.
*Heart Rate ↓ Blood Pressure ↓ Systemic Vascular Resistance ↑*
- An increase in **IP3 in arteriolar smooth muscle cells** would cause **vasoconstriction (increased SVR)**, which tends to increase blood pressure, not decrease it.
- An increase in **cAMP in cardiac myocytes** would increase heart rate and contractility through β1 stimulation, not decrease them.
*Heart Rate ↑ Blood Pressure ↑ Systemic Vascular Resistance ↓*
- While heart rate and blood pressure would increase due to the drug's effects on cardiac myocytes, the increased IP3 in arteriolar smooth muscle cells would lead to **vasoconstriction** and thus an **increase in systemic vascular resistance**, not a decrease.
- A decrease in systemic vascular resistance would typically lower blood pressure unless cardiac output increases significantly to compensate.
*Heart Rate ↑ Blood Pressure ↓ Systemic Vascular Resistance ↓*
- The drug's mechanism of action, particularly the increase in **IP3 leading to vasoconstriction**, is fundamentally inconsistent with a decrease in both blood pressure and systemic vascular resistance.
- While heart rate would increase via β1 stimulation, decreased BP with decreased SVR contradicts the described α1-mediated vascular effects.
*Heart Rate No change Blood Pressure ↑ Systemic Vascular Resistance ↑*
- The increase in **cAMP in cardiac myocytes** directly stimulates **β1 adrenergic receptors**, leading to increased **heart rate**, not "no change."
- While **blood pressure** and **systemic vascular resistance** would correctly increase, the absence of heart rate change is inconsistent with the drug's β1 agonist effects on the heart.
Question 190: A 64-year-old man presents to the emergency department with sudden onset of pleuritic chest pain and dyspnea on exertion. He has a history of lung cancer and is currently being treated with outpatient chemotherapy. His temperature is 98.9°F (37.2°C), blood pressure is 111/64 mmHg, pulse is 130/min, respirations are 25/min, and oxygen saturation is 90% on room air. Initial laboratory values in the emergency department are seen below.
Hemoglobin: 8.2 g/dL
Hematocrit: 26%
Leukocyte count: 7,700/mm^3 with normal differential
Platelet count: 157,000/mm^3
A CT angiogram demonstrates a blood clot in the pulmonary vasculature. The patient is started on heparin and he is admitted to the ICU. Laboratory values 6 days later are shown below.
Hemoglobin: 8.0 g/dL
Hematocrit: 25%
Leukocyte count: 7,500/mm^3 with normal differential
Platelet count: 22,000/mm^3
Which of the following is the most appropriate next step in management?
A. Platelet transfusion
B. No treatment changes needed
C. Blood transfusion
D. Stop heparin (Correct Answer)
E. Start warfarin
Explanation: ***Stop heparin***
- The patient's **platelet count dropped significantly** from 157,000/mm³ to 22,000/mm³ after 6 days of heparin, strongly suggesting **heparin-induced thrombocytopenia (HIT)**.
- In suspected HIT, **heparin must be immediately discontinued** and an alternative non-heparin anticoagulant initiated to prevent thrombotic complications.
*Platelet transfusion*
- **Platelet transfusions are generally contraindicated in HIT** unless there is severe, life-threatening bleeding, as they may worsen the prothrombotic state.
- The primary concern in HIT is the **paradoxical thrombosis risk**, not simply the low platelet count itself.
*No treatment changes needed*
- The **precipitous drop in platelet count** to 22,000/mm³ in a patient on heparin is a critical finding requiring immediate action due to the high risk of paradoxical thrombosis.
- Ignoring this significant laboratory change would lead to potential harm from **thrombotic events** associated with HIT.
*Blood transfusion*
- While the patient's hemoglobin is low (8.0 g/dL), a blood transfusion is not the most immediate or appropriate next step in managing a suspected case of **heparin-induced thrombocytopenia (HIT)**.
- The primary and most urgent concern is the dangerously low and rapidly falling platelet count in the context of heparin use.
*Start warfarin*
- **Warfarin should not be initiated as monotherapy in HIT** until therapeutic anticoagulation is achieved with a non-heparin agent.
- Starting warfarin in the acute phase before stopping heparin can lead to a rapid drop in protein C, increasing the risk of **venous limb gangrene**.